Categories
Biotech Stocks Coronavirus Featured Investing Stocks to Watch

Looking For The Best Biotech Stocks To Trade On Robinhood? 2 To Watch

Are these popular biotech stocks on Robinhood worth the attention?

Are You Looking For Top Biotech Stocks To Buy? If Yes, Are These 2 On Your List?

Biotech stocks have emerged as a popular asset class to watch this year. More specifically, small-cap biotech stocks are making big moves like never before. For this reason, it is gathering a lot of investor attention to find the next big thing to bet on. That’s understandable with everything that’s going on with the COVID-19 pandemic. At the same time, quite a number of otherwise promising businesses have slipped under the radar. The increasing participation in the small-cap biotech stocks space is increasingly evident, especially among Robinhood investors.

Small-cap stocks are famous for their notorious movement in share prices. Some have even returned more than a thousand percent. If you look at some of the top biotech stocks to buy today, a few of them have all started as small-cap biotech stocks this year. And next thing you know, they reached similar valuations as other well-established companies. Amongst them are Moderna (MRNA Stock Report) and Novavax (NVAX Stock Report), just to name a few. If you look at some of the most active biotech stocks in the space, chances of you seeing overnight breakout are common.

That said, if you do the research and studies, with excellent timing, you might gain a thousand percentage gains in a few days’ time. But in most cases, something so speculative might be another pump and dump scheme, where gains quickly become losses. 

While looking for biotech small-cap stocks, instead of looking at their quarterly reports, you might be better off keeping track of filings and dates of clinical trials. These will essentially give you the upper hand in trading before the press release. So if you find some biotech stocks you want to add to your watchlist, doing some research could help. That said, let us see if these are the best biotech stocks to buy in August 2020.

Read More

Top Biotech Stocks To Buy [Or Avoid] Among Robinhood Investors: Catalyst Pharma

First, on the list, you could argue that Catalyst Pharma (CPRX Stock Report) was an under the radar biotech stocks. The company’s market capitalization stood at around $370 million. They were under the radar for the right reasons. Revenue and earnings fell year over year in the most recent quarter.

In addition, the company reported disappointing results from a late-stage clinical study evaluating Firdapse in treating patients with neuromuscular disease anti-MuSK antibody positive myasthenia gravis. Last year, the drug also failed to deliver in a late-stage study targeting a rare neuromuscular disorder known as congenital myasthenic syndromes (CMS). But the drug has already received approval in the US and Canada for treating autoimmune disease Lambert-Eaton myasthenic syndrome (LEMS). Although the COVID-19 pandemic negatively affected second-quarter revenue, the company is now seeing some improvement. The company is also seeking regulatory approval for Firdapse in Japan as a treatment for LEMS.

The company also expects to announce results from a phase 1 study later this year evaluating Firdapse in treating spinal muscular atrophy type-3. Furthermore, Catalyst Pharma is exploring opportunities to acquire another product or company. The question is, can CPRX stock see some catalysts in the coming weeks?

[Read More] Top Semiconductor Stocks To Buy On Data Center Strength

Top Biotech Stocks To Buy [Or Avoid] Among Robinhood Investors: Corbus Pharmaceuticals

Corbus Pharma (CRBP Stock Report) is a clinical-stage drug development company developing medicines for inflammatory and fibrotic diseases. The company’s lead drug candidate is Lenabasum, a potential treatment for systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus is slated to announce the phase 3 results this summer. Should the data be positive, the company could be in a good position to win big after successful FDA registration.

Besides, the company expects to report topline results from a phase 2b study of lenabasum in treating cystic fibrosis patients at high risk for recurrent pulmonary exacerbation this quarter. It is also aiming to announce topline data from a phase 3 study of the drug in treating autoimmune disease dermatomyositis late next year.

Furthermore, investors could also expect the company to add a few more pipeline candidates on top of the existing ones in the near future. Most of the company’s drugs are still in the R&D stage. Therefore, if you are considering CRBP stock, I would suggest paying close attention to the Lenabasum drug for now. that’s until there are updates from other pipeline drugs.

By Amos C

Amos is the global markets correspondent for StockMarket.com. His boots on the ground insight into emerging markets has given him the unique ability to stay ahead of new market trends and deliver timely data when it matters most. Based in Asia, Amos has made a point to monitor the foreign markets closely, dissect stock market trends and then apply them to the North American markets; in addition to global markets.

Amos has a deep-rooted background in foreign exchange and commodities. His previous experience working within the cryptocurrency arena has given him the advantage to identify the fast-moving stock market and financial trends. Amos calls Hong Kong home and has been a financial content writer for the last 3 years.

He has managed teams of international media strategists and financial writers to cover all top stories in the stock market each day. His skills include his tireless drive to find the most valid information and actionable details that investors can use to formulate valid decisions on stocks to buy or stocks to avoid. Furthermore, Amos’ ability to cover trending stories across the globe brings StockMarket.com a fresh perspective on key data and how it not only affects the North American markets but also how it could translate to the world markets alike.

Most of the time you can find him diving into corporate filings, focusing on fundamentals that could influence major market moves. One of his passions is researching technology and biotechnology stocks. Some of the most cutting-edge innovations have stemmed from these industries. While many don’t become industry blockbusters, the processes and applications of these innovations has led to some of the biggest developments known to man in the modern age. As a global correspondent, Amos has been able to see both sides of the story as it relates to world news and offers a true, personal approach, cutting through the noise of the mass media. He was integral in reporting on the Hong Kong uprising and doing first-hand research on international sentiment from the novel coronavirus.

In his free time, Amos is an avid fan of music and art and enjoys attending concerts.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments